ASSESSMENT OF PROGNOSTIC FACTORS ASSOCIATED WITH ANTI-OXIDATIVE STATUS IN END STAGE RENAL DISEASE PATIENTS EXPERIENCE SURGICAL TRIAL
Main Article Content
Keywords
CKD, MDA, SOD, CAT, IL-2, TNF-ALPHA
Abstract
Background: End Stage Renal Disease (ESRD) or Chronic kidney disease (CKD) is a group of diverse deformities that upshot the physiology and anatomy of the kidney. Kidney failure is the most severe outcome of the chronic kidney disease.
Methodology: Comparative study. Sixty patients of End Stage Renal Disease (ESRD) and Fourty five age and gender matched clinically evidently fit persons were entitled for incorporation in the study. 5 ml blood sample were drawn and subjected to centrifuge at 4000-5000 rpm for 15 minutes for the separation of serum. Serum MDA, SOD, CAT, GSH, VIT A, VIT C, VIT E, Nitric oxide (NO), Neuraminidase, Electrolytes TNF-alpha and IL-2 were estimated. Results: Serum Sodium (Na+) level in the ESRD patients was elevated (179.53±3.26) as compared to control (147.26±4.26) and significant statistically (0.04<0.05). Serum Potassium level (K+) was also raised in the ESRD patients (16.12±5.26) as compared to control group (11.09±3.26) and also statistically substantial (0.03<0.05). Vitamin A level in ESRD patients was decreased (87.99±5.26) as compared to healthy subjects (102.25±14.26) and statistically substantial (0.002<0.05). MDA level shows elevated level in ESRD patients (8.06±1.5) as compared to control (1.25±0.65) and statistically significant (0.045<0.05).
Conclusion: Present study showed that there is a correlation exist between Oxidative stress, Vitamins, Electrolytes, IL-2, TNF-alpha and CKD. These results indicate a perfect description related to circulating biomarkers and lipid peroxidation. Increased level of MDA as a biomarker of lipid peroxidation, increased IL-2 and TNF-alpha and Nitric oxide (NO) level is the cause for the progression of the disease.
References
2. Levey AS, Coresh J, Balk E. for the National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 139 (2003) 137-47.
3. Levey AS, Eckardt KU, Tsukamoto Y. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 67 (2005). 2089-2100.
4. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis. 53 (3) (2009). S4-16.
5. Rettig RA, Norris K, Nissenson AR. Chronic kidney disease in the United States: a public policy imperative. Clin J Am SocNephrol. 3 (2008) 1902-1910.
6. Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis. A position statement from KDOQI and KDIGO. Am J Kidney Dis. 53 (2009) 915-920.
7. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 74 (2008) 101-07.
8. James MT, Hemmelgarn BR, Wiebe N. for the Alberta Kidney Disease Network. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet. 376 (2010) 2096-2103.
9. James, MT Quan H, Tonelli M. for the Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 54 (2009) 24-32.
10. Hailpern SM, Melamed ML, Cohen HW, Hostetter TH. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am SocNephrol. 18 (2007) 2205-2213.
11. Wilhelm-Leen ER, Hall YN, Tamura MK, Chertow GM. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med. 122 (2009) 664-671.
12. Housman AE, Shropshire LA. Incidence and prevalence. United States Renal Data System. 2010 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. (2010). 2 Atlas of ESRD.
13. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 41 (2003) 1-12.
14. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 300 (1990) 297-300.
15. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 28 (1997) 557-63.
16. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 56 (1999) 2214-2219.
17. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am CollCardiol. 38: (2001) 705-711.
18. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 134: (2001) 629-36.
19. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 37: (2001) 1069-1074.
20. Klahr S, Levey AS, Beck GJ. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal failure. N Engl J Med. 330: (1994) 877-884.
21. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end stage renal disease. Kidney Int. 63: (2003) 1468-1473.
22. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 339: (1998) 1448-1456.
23. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a Collaborative Transplant Study report. Am J Transplant. 4: (2004) 222-230.
24. Beveridge T, Gratwohl A, Michot F. cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts. currther res. 30: (1981) 5-18.
25. Laupacis A. For the canadian transplant study group. complications of cyclosporine therapy-a comparison to azathioprine. transplant proc. 15: (1983) 2748-53.
26. Mezzano D, Pais EO, Aranda E. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 60: (2001) 1844-1850.
27. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. J Anal Biochem, 95: (1979) 351-358.
28. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometer assay of superoxide dismutase. Indian J Biochem Bio.21: (1984) 130-132.
29. Aebi H. Catalase in Bergmeyer HU (eds.). Methods in Enzymatic Analysis, Academic Press. New York. pp. (1984) 276-286.
30. Moron MS, Depierre J, Mannervik B. Levels of glutathione, glutathione reductase and glutathione-S-transferase activities in rat lung and liver. BiochemBiophysActa, 582: (1979) 67-78.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Hafiz Muhammad Arsalan
International Faculty of General Medicine, Altamimi International Medical University, Bishkek-Kyrgyzstan.
Uraiimov Elaman Toktobolotovich
Department of Pathology, International School of Medicine, International University of Kyrgyzstan, Kyrgyzstan.
Muhammad Shoaib Ramzan
Department of Pathology, Adan Hospital, Kuwait.
Munib Ashfaq
Department of Biochemistry, University of Gujrat-Pakistan.